Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue

Timothy M. Clay, Mary C. Custer, Mark D. McKee, Maria Parkhurst, Paul F. Robbins, Keith Kerstann, John Wunderlich, Steven A. Rosenberg, Michael I. Nishimura

Research output: Contribution to journalArticle

Abstract

In a recent clinical trial, HLA-A2+ melanoma patients were vaccinated with a peptide derived from the melanoma Ag gp100, which had been modified at the second position (g9-209 2M) to enhance MHC binding affinity. Vaccination led to a significant increase in lymphocyte precursors in 10 of 11 patients but did not result in objective cancer responses. We observed that some postvaccination PBMC cultures were less reactive with tumor cells than they were with g9-209 peptide-pulsed T2 cells. in contrast, g9-209-reactive tumor- infiltrating lymphocyte cultures generally reacted equally with tumor cells and g9-209 peptide-pulsed T2 cells. To investigate this differences in T cell reactivity, T cell cloids derived from the PBMC of three patients vaccinated with g9-209 2M were compared with T cell cloids isolated from g9-209-reactive TIL cultures. All of the T cell cloids obtained from TIL reacted with HLA- A2+, gp100+ melanoma cell lines as well as with g9-209 and g9-209 2M peptide-pulsed targets. In contrast, only 3 of 20 PBMC-derived T cell cloids reacted with melanoma cell lines in addition to g9-209 and to g9-209 2M peptide-pulsed targets. Twelve of twenty PBMC-derived cloids reacted with g9- 209 and g9-209 2M peptide-pulsed targets but not with melanoma cell lines. And 5 of 20 PBMC-derived cloids recognized only the g9-209 2M-modified peptide-pulsed targets. These results suggest that immunizing patients with the modified peptide affected the T cell repertoire by expanding an array of T cells different fine specificities, only some of which recognized melanoma cells.

Original languageEnglish (US)
Pages (from-to)1749-1755
Number of pages7
JournalJournal of Immunology
Volume162
Issue number3
StatePublished - Feb 1 1999
Externally publishedYes

Fingerprint

Vaccination
Melanoma
T-Lymphocytes
Peptides
HLA-A2 Antigen
Cell Line
Peptide T
Tumor-Infiltrating Lymphocytes
Neoplasms
Clinical Trials
Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Clay, T. M., Custer, M. C., McKee, M. D., Parkhurst, M., Robbins, P. F., Kerstann, K., ... Nishimura, M. I. (1999). Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. Journal of Immunology, 162(3), 1749-1755.

Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. / Clay, Timothy M.; Custer, Mary C.; McKee, Mark D.; Parkhurst, Maria; Robbins, Paul F.; Kerstann, Keith; Wunderlich, John; Rosenberg, Steven A.; Nishimura, Michael I.

In: Journal of Immunology, Vol. 162, No. 3, 01.02.1999, p. 1749-1755.

Research output: Contribution to journalArticle

Clay, TM, Custer, MC, McKee, MD, Parkhurst, M, Robbins, PF, Kerstann, K, Wunderlich, J, Rosenberg, SA & Nishimura, MI 1999, 'Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue', Journal of Immunology, vol. 162, no. 3, pp. 1749-1755.
Clay, Timothy M. ; Custer, Mary C. ; McKee, Mark D. ; Parkhurst, Maria ; Robbins, Paul F. ; Kerstann, Keith ; Wunderlich, John ; Rosenberg, Steven A. ; Nishimura, Michael I. / Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. In: Journal of Immunology. 1999 ; Vol. 162, No. 3. pp. 1749-1755.
@article{61de4f860b5c4aaeae4d28694af43b63,
title = "Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue",
abstract = "In a recent clinical trial, HLA-A2+ melanoma patients were vaccinated with a peptide derived from the melanoma Ag gp100, which had been modified at the second position (g9-209 2M) to enhance MHC binding affinity. Vaccination led to a significant increase in lymphocyte precursors in 10 of 11 patients but did not result in objective cancer responses. We observed that some postvaccination PBMC cultures were less reactive with tumor cells than they were with g9-209 peptide-pulsed T2 cells. in contrast, g9-209-reactive tumor- infiltrating lymphocyte cultures generally reacted equally with tumor cells and g9-209 peptide-pulsed T2 cells. To investigate this differences in T cell reactivity, T cell cloids derived from the PBMC of three patients vaccinated with g9-209 2M were compared with T cell cloids isolated from g9-209-reactive TIL cultures. All of the T cell cloids obtained from TIL reacted with HLA- A2+, gp100+ melanoma cell lines as well as with g9-209 and g9-209 2M peptide-pulsed targets. In contrast, only 3 of 20 PBMC-derived T cell cloids reacted with melanoma cell lines in addition to g9-209 and to g9-209 2M peptide-pulsed targets. Twelve of twenty PBMC-derived cloids reacted with g9- 209 and g9-209 2M peptide-pulsed targets but not with melanoma cell lines. And 5 of 20 PBMC-derived cloids recognized only the g9-209 2M-modified peptide-pulsed targets. These results suggest that immunizing patients with the modified peptide affected the T cell repertoire by expanding an array of T cells different fine specificities, only some of which recognized melanoma cells.",
author = "Clay, {Timothy M.} and Custer, {Mary C.} and McKee, {Mark D.} and Maria Parkhurst and Robbins, {Paul F.} and Keith Kerstann and John Wunderlich and Rosenberg, {Steven A.} and Nishimura, {Michael I.}",
year = "1999",
month = "2",
day = "1",
language = "English (US)",
volume = "162",
pages = "1749--1755",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue

AU - Clay, Timothy M.

AU - Custer, Mary C.

AU - McKee, Mark D.

AU - Parkhurst, Maria

AU - Robbins, Paul F.

AU - Kerstann, Keith

AU - Wunderlich, John

AU - Rosenberg, Steven A.

AU - Nishimura, Michael I.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - In a recent clinical trial, HLA-A2+ melanoma patients were vaccinated with a peptide derived from the melanoma Ag gp100, which had been modified at the second position (g9-209 2M) to enhance MHC binding affinity. Vaccination led to a significant increase in lymphocyte precursors in 10 of 11 patients but did not result in objective cancer responses. We observed that some postvaccination PBMC cultures were less reactive with tumor cells than they were with g9-209 peptide-pulsed T2 cells. in contrast, g9-209-reactive tumor- infiltrating lymphocyte cultures generally reacted equally with tumor cells and g9-209 peptide-pulsed T2 cells. To investigate this differences in T cell reactivity, T cell cloids derived from the PBMC of three patients vaccinated with g9-209 2M were compared with T cell cloids isolated from g9-209-reactive TIL cultures. All of the T cell cloids obtained from TIL reacted with HLA- A2+, gp100+ melanoma cell lines as well as with g9-209 and g9-209 2M peptide-pulsed targets. In contrast, only 3 of 20 PBMC-derived T cell cloids reacted with melanoma cell lines in addition to g9-209 and to g9-209 2M peptide-pulsed targets. Twelve of twenty PBMC-derived cloids reacted with g9- 209 and g9-209 2M peptide-pulsed targets but not with melanoma cell lines. And 5 of 20 PBMC-derived cloids recognized only the g9-209 2M-modified peptide-pulsed targets. These results suggest that immunizing patients with the modified peptide affected the T cell repertoire by expanding an array of T cells different fine specificities, only some of which recognized melanoma cells.

AB - In a recent clinical trial, HLA-A2+ melanoma patients were vaccinated with a peptide derived from the melanoma Ag gp100, which had been modified at the second position (g9-209 2M) to enhance MHC binding affinity. Vaccination led to a significant increase in lymphocyte precursors in 10 of 11 patients but did not result in objective cancer responses. We observed that some postvaccination PBMC cultures were less reactive with tumor cells than they were with g9-209 peptide-pulsed T2 cells. in contrast, g9-209-reactive tumor- infiltrating lymphocyte cultures generally reacted equally with tumor cells and g9-209 peptide-pulsed T2 cells. To investigate this differences in T cell reactivity, T cell cloids derived from the PBMC of three patients vaccinated with g9-209 2M were compared with T cell cloids isolated from g9-209-reactive TIL cultures. All of the T cell cloids obtained from TIL reacted with HLA- A2+, gp100+ melanoma cell lines as well as with g9-209 and g9-209 2M peptide-pulsed targets. In contrast, only 3 of 20 PBMC-derived T cell cloids reacted with melanoma cell lines in addition to g9-209 and to g9-209 2M peptide-pulsed targets. Twelve of twenty PBMC-derived cloids reacted with g9- 209 and g9-209 2M peptide-pulsed targets but not with melanoma cell lines. And 5 of 20 PBMC-derived cloids recognized only the g9-209 2M-modified peptide-pulsed targets. These results suggest that immunizing patients with the modified peptide affected the T cell repertoire by expanding an array of T cells different fine specificities, only some of which recognized melanoma cells.

UR - http://www.scopus.com/inward/record.url?scp=0033082514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033082514&partnerID=8YFLogxK

M3 - Article

VL - 162

SP - 1749

EP - 1755

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -